#United States #San Francisco #VYKAT XR #Soleno Therapeutics #Hyperphagia

Soleno Therapeutics Faces Class Action Amid Launch Challenges

In a troubling turn of events for Soleno Therapeutics, Inc. (NASDAQ: SLNO), a class action lawsuit has been filed, representing investors who bought shares between March 26, 2025, and November 4, 2025. This legal action comes on the heels of the company’s disappointing announcement regarding their new hyperphagia treatment, DCCR (marketed as VYKAT™ XR).

Disruption in Launch Trajectory

The legal woes began shortly after Soleno released its Q3 2025 earnings call on November 4, 2025, where management disclosed that their launch trajectory was disrupted due to reports from an activist short seller, Scorpion Capital, which raised serious questions about the drug's safety and efficacy. This revelation followed a steep 26% drop in the stock's value on the report day, a clear indicator of investor panic and dissatisfaction.

Allegations of Misrepresentation

The core of the lawsuit centers around claims that Soleno misrepresented the safety and commercial potential of VYKAT™ XR. The company touted the launch's success and great commercial prospects, stating it was performing far above expectations. However, the lawsuit argues that these statements were misleading and did not disclose significant safety concerns related to the drug’s administration, particularly regarding cases of excess fluid retention observed during clinical trials.

Accusations have emerged that the company strategically concealed these risks, leading to questions about the reliability of their Phase 3 clinical program. Investors are troubled by the allegations that DCCR poses greater risks than Soleno leaders conveyed, with the drug’s viability in the market now called into question.

Investor Reactions and Market Response

On August 15, 2025, prior to the stock's dramatic plunge, Scorpion Capital began shedding light on what they described as alarming side effects, including children being hospitalized due to potential heart failure after using VYKAT™ XR. They characterized Soleno’s launch metrics as questionable, heavily relying on a controversial physician involved in critical trials, prompting calls for transparency and integrity in their data.

In the wake of these claims, Soleno has faced mounting pressure to clarify their stance and provide concrete evidence of DCCR’s efficacy and safety, while also addressing apparent discrepancies in their communication with investors.

Ongoing Investigation and Future Steps

Hagens Berman, the law firm leading the class action suit, has urged affected investors to step forward as the investigation unfolds. The firm is working diligently to assess whether Soleno may have indeed misled investors regarding the launch and commercial prospects of VYKAT™ XR. Timing is crucial, as the lead plaintiff deadline is set for May 5, 2026.

Conclusion

As the situation develops, many investors remain on edge about their stake in Soleno Therapeutics. With the stock’s value plummeting nearly 40% since the activist report, the path forward for the company and its investors will hinge on the outcomes of this class action lawsuit and ongoing investigations. Those who purchased stock during the specified period are encouraged to seek legal counsel and document their losses, ensuring their voices are heard in this critical period for corporate accountability.